Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022

Prophylactic Hepatitis B Virus Vaccines - Global Drug Forecast and Market Analysis to 2022 report provide Vaccine Manufacturers Seek To Increase Vaccine Uptake By Developing Pediatric Combination Vaccines And Adult Adjuvanted Vaccines. Over the last two decades, the HBV vaccine market has largely been dominated by Big Pharma, with GSK, MERCK, AND SANOFI as the key players. While GSK and Merck were the first companies to introduce recombinant HBsAg containing vaccines in the 1980s, GSK has entrenched itself as the clear market leader, $1.1 Billion Global Sales By 2022.